Two law firms that filed competing class actions against regenerative medicine company Mesoblast for allegedly misleading shareholders about its Remestemcel-L treatment for COVID-19 complications have agreed to join forces and sidestep a beauty parade.
Former prime minister Scott Morrison has defended his decision to appoint himself as shadow minister of significant government portfolios during the COVID-19 pandemic, saying the times were extraordinary and the actions were taken as an emergency safeguard.
Ambulance Victoria is being sued by a former executive who claims she was not treated the same as her male colleagues and was subject to “disrespectful, undermining” conduct from senior colleagues.
Samsung Bioepis Australia has sued fellow biotechnology company Fresenius Kabi over a biosimilar of top selling immunosuppressant drug Humira, saying the invention ‘does not achieve the promise’ of a better formulation using fewer ingredients.
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.
Publisher HarperCollins has filed a special leave application with the High Court seeking to challenge a decision that revived a defamation case by a psychiatrist over a book covering the controversial deep sleep therapy at the Chelmsford Private Hospital in the 1970s.
German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.
US medical device maker Boston Scientific has agreed to pay $105 million to settle a class action on behalf of Australian women implanted with one or more of the company’s pelvic mesh or sling products.
A judge has dismissed a proceeding against the New South Wales government over a mandate requiring healthcare workers to be vaccinated against COVID-19, saying the applicant’s constitutional case was “legally misconceived and must be rejected.”
Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.